1428761-24-3

Basic information

• Product Name: 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid
• Synonyms: 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid
• CAS NO: 1428761-24-3
• Molecular Weight: 229.62
• Mol File: 1428761-24-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid(1428761-24-3)
• EPA Substance Registry System: 2-(2-chloro-5-methyl-4-nitrophenyl)acetic acid(1428761-24-3)

Safety Data

• Hazardous Substances Data: 1428761-24-3(Hazardous Substances Data)

Upstream product

• 1428761-23-2 1-allyl-2-chloro-5-methyl-4-nitrobenzene 
• 57310-39-1 2-bromo-1-chloro-4-methylbenzene 

Downstream Products

• 1432909-83-5 methyl 2-(2-chloro-5-methyl-4-(6-methylpyrazin-2-yl)phenyl)acetate 
• 192650-79-6 methyl 2-(4-amino-2-chloro-5-methylphenyl)acetate 
• 1428761-26-5 methyl 2-(4-bromo-2-chloro-5-methylphenyl)acetate 
• 1432909-81-3 methyl 2-(2-chloro-5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 
• 1432909-88-0 methyl 2-(2-chloro-5-methyl-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)acetate 
• 1432909-85-7 methyl 2-(2-chloro-4-cyano-5-methylphenyl)acetate 
• 1432909-86-8 methyl 2-(2-chloro-4-(N-hydroxycarbamimidoyl)-5-methylphenyl)acetate 
• 1428761-27-6 methyl 2-(2-chloro-5-methyl-4-(pyridin-3-yl)phenyl)acetate 
• 1428761-25-4 methyl 2-(2-chloro-5-methyl-4-nitrophenyl)acetate 

Relevant articles and documents

ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND

To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2/su

8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H) -ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER

Provided herein are PAK inhibitors and methods of utilizing PAK inhibitors for the treatment of CNS disorders such as neuropsychiatric disorders or neurofibromatosis. Also described herein are methods of utilizing PAK inhibitors for the treatment of cancer.